On June 7, Aduhelm (aducanumab) became the first new treatment for Alzheimer’s disease to be approved by the U.S. Food and Drug Administration (FDA) in nearly two decades, and this disorder’s first targeted therapy. Scarcely a month later, the agency took the unusual step of updating its label for the newly approved medication. It revised broad language that simply indicated Aduhelm “for the treatment of Alzheimer’s disease” to language limiting first use to “patients with…
You must be logged in to read/download the full post.
The post Amid Concerns, Aduhelm ‘Moving Forward’ as 1st Targeted Therapy appeared first on BioNewsFeeds.